Cti Biopharma reported $29.77M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Baxter International BAX:US USD 3.71B 208M
Cti Biopharma CTIC:US USD 29.77M 19K
Cytori Therapeutics CYTX:US USD 7.42M 449K
Geron GERN:US USD 82.81M 35.93M
Mirati Therapeutics MRTX:US USD 126.99M 7.84M
Northwest Biotherapeutics NWBO:US USD 116.13M 17.97M
Novartis NVS:US USD 28.66B 496M
Novartis NOVN:VX USD 28.16B 514M
Seattle Genetics SGEN:US USD 726M 117.48M
Teva Pharmaceutical Industries TEVA:US USD 11.53B 538M
YTE INCY:US USD 1.01B 79.92M